XSHG
688363
Aug 05, Last price
51.59
1D
0.47%
1Q
7.06%
IPO
-45.18%
Name
Bloomage Biotechnology Corp Ltd
Chart & Performance
P/E
—
P/S
—
EPS
3.05
Div Yield, %
0.74%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
6.08b
Net income
593m
CFO
700m
Dividend
Aug 08, 20240.38 /sh
Profile
Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers pharmaceutical grade sodium hyaluronate which can be used as an API or excipient for drugs and medical devices in ophthalmic preparations, intra-articular injections, anti-adhesive preparations, and topical preparations for wound healing and soft tissue filler under the Hyature name; and cosmetic grade sodium hyaluronate solutions for cosmetic products, including moisturizing, repairing, delay skin aging, and brightening under the Hybloom, miniHA, microHA, Hyacross, Hyacolor, and cationHA. The company also provides food-grade sodium hyaluronate for use in food/healthy food/dietary supplements under the HAPLEX name, as well as food-grade gamma aminobutyric acid under the Gabarelax name; hyaluronic acid for oral care under the Biomoist name; and animal care products under the HYAPET names. Bloomage BioTechnology Corporation Limited was founded in 2000 and is headquartered in Jinan, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 6,075,924 | ||||||||
Cost of revenue | 5,048,719 | ||||||||
Unusual Expense (Income) | |||||||||
NOPBT | 1,027,205 | ||||||||
NOPBT Margin | 16.91% | ||||||||
Operating Taxes | 118,980 | ||||||||
Tax Rate | 11.58% | ||||||||
NOPAT | 908,224 | ||||||||
Net income | 592,556 | ||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (105,891) | ||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 106,084 | ||||||||
Long-term debt | 107,628 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 205,729 | ||||||||
Net debt | (1,598,042) | ||||||||
| Cash flow | |||||||||
Cash from operating activities | 699,648 | ||||||||
CAPEX | (1,030,331) | ||||||||
Cash from investing activities | (620,664) | (836,222) | |||||||
Cash from financing activities | (533,566) | ||||||||
FCF | (3,504,016) | ||||||||
| Balance | |||||||||
Cash | 1,308,759 | ||||||||
Long term investments | 502,994 | ||||||||
Excess cash | 1,507,957 | ||||||||
Stockholders' equity | 2,974,889 | 481,085 | |||||||
Invested Capital | 5,842,254 | ||||||||
ROIC | 15.55% | ||||||||
ROCE | 13.97% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 481,753 | 483,044 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | 1,291,858 | ||||||||
EV/EBITDA | |||||||||
Interest | 10,736 | ||||||||
Interest/NOPBT | 1.05% | ||||||||